{"disease":{"id":"germline-mutation","name":"germline mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04585074","title":"Prospective Study of MAstectomy With Reconstruction Including Robot Endoscopic Surgery","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Severance Hospital","has_results":false},{"nct_id":"NCT03982446","title":"Germline Mutations in Pancreatic Adenocarcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":549,"lead_sponsor_name":"Hellenic Cooperative Oncology Group","has_results":false},{"nct_id":"NCT07019155","title":"Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants","phase":"","overall_status":"RECRUITING","enrollment_count":510,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04296370","title":"A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":474,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT07204392","title":"Unveiling the Germline Predisposition to Myeloproliferative Neoplasms","phase":"","overall_status":"RECRUITING","enrollment_count":313,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT03286842","title":"To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":256,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04983628","title":"Molecular Profiling in Prostate Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Hellenic Cooperative Oncology Group","has_results":false},{"nct_id":"NCT04668521","title":"Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection","phase":"","overall_status":"TERMINATED","enrollment_count":215,"lead_sponsor_name":"Aspira Women's Health","has_results":false},{"nct_id":"NCT05072483","title":"Natural History Study of CADASIL","phase":"","overall_status":"RECRUITING","enrollment_count":155,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT02184195","title":"Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04584255","title":"Niraparib + Dostarlimab In BRCA Mutated Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":62,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT04090567","title":"Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05097274","title":"The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation.","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Institute of Cancer Research, United Kingdom","has_results":false},{"nct_id":"NCT04965597","title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT02821780","title":"CADASIL Disease Discovery","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT04770246","title":"TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}